The estrogen receptor (ER) stimulates transcription of target genes by means of its two transcriptional activation domains, (25, 26) , and this is accompanied by an inhibition of nuclear uptake of the receptor during nucleocytoplasmic shuttling (27) .
Estrogens regulate target cell proliferation, growth, and differentiation through a defined sequence of molecular events triggered by their binding to the intracellular estrogen receptor (ER) (1) (2) (3) (4) (5) (6) (7) . The receptor functions directly as a liganddependent transcription factor as shown in different species (8) (9) (10) (11) (12) (13) . Transcriptional activation is mediated by AF-1 in the N-terminal domain and AF-2 in the C-terminal hormonebinding domain (1) (2) (3) (4) (5) (6) (7) . Since (14, 15) .
The antiestrogen tamoxifen is a leading therapeutic agent in the treatment of ER-positive primary breast cancers (14) (15) (16) (17) and in large chemopreventive trials with healthy candidates (18, 19) . Tamoxifen or its potent metabolite 4-hydroxytamoxifen (4-OHT) competes with estrogen for binding to ER and blocks the transcriptional activity of the receptor (15, (20) (21) (22) . However, tamoxifen has a complex pharmacological behavior, as it can present either antagonistic or agonistic activities in a species-, tissue-, and cell type-dependent fashion (16, 20) . Moreover, only half of ER-positive breast tumors respond to tamoxifen therapy, and a majority of them relapse into antiestrogen-unresponsive tumors even though ER is often still measurable by ligand-binding assays (14, 15) . The unpredictability of the side effects of tamoxifen and the frequent recurrence of tumors in patients undergoing tamoxifen therapy have stimulated the search for more potent antiestrogens devoid of agonistic activity. Along this line of investigation, it
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was demonstrated that the estradiol derivatives ICI 164,384
and ICI 182,780 bind to the ER and are pure antagonists (21, 23, 24) . They have been shown to reduce the cell content of ERs by increasing their turnover (25, 26) , and this is accompanied by an inhibition of nuclear uptake of the receptor during nucleocytoplasmic shuttling (27) .
In this paper, we demonstrate that certain point mutations in the ligand-binding domain of the ER alter dramatically the responsiveness of the mutated ERs not only to estrogen but more importantly to antiestrogens. Two mutants are described whose activation by estrogen is abolished but are instead strong transcriptional activators in response to stimulation by both 4-OHT and the pure antiestrogen ICI 164,384.
MATERIALS AND METHODS
Receptor Expression Vectors and Reporter Gene Constructs. The isolation of mouse ER (MOR) cDNA clones, the construction of mutants thereof, and their transfer into the pJ3f expression vector have been described (28, 29) . Missense mutants of the full-length protein [MOR-(1-599)] were generated and named according to the position and identity of the substituted amino acid and the substituting residue-e.g., L543A indicates replacement of leucine at position 543 by alanine. Deletion mutants are described by the remaining amino acids-e.g., MOR-(121-599) is an N-terminal deletion mutant starting at methionine-121. The reporter construct pERE BLCAT contains the estrogen-responsive element (ERE) from the Xenopus vitellogenin A2 promoter (30, 31) , which was cloned upstream of the herpes simplex virus thymidine kinase gene promoter driving expression of the chloramphenicol acetyltransferase (CAT) coding sequences (28) . pRSV-luc encodes luciferase expressed under the control of the Rous sarcoma virus (RSV) promoter (32 (32) and CAT (33) activities. For the production of receptor used in gel retardation assays, Cos-1 cells were electroporated with the receptor expression vectors and pRSV-luc as described (29) . Whole cell extracts (WCEs) were prepared as described (29) and assayed for luciferase activity (32) .
DNA-Binding Analyses. DNA-binding activity in WCE from Cos-1 cells that expressed wild-type or mutant MORs was measured by using a gel retardation assay. DNA-binding reaction mixtures containing [10] [11] [12] [13] [14] [15] (27) . Untransfected or transfected cells incubated without H222 antibody were included as controls.
AF-1 RESULTS
Previous mutant analyses have shown that a segment of AF-2 comprising residues 538-552 in MOR is essential for hormonedependent activation of transcription (29) . This region, which is conserved in the ER from different species and also in several other nuclear receptors, contains two pairs of hydrophobic amino acids (L543/L544, M547/L548) and a negatively charged glutamic acid residue (E546) and is flanked by additional negatively charged aspartic acid residues, D542 and D549 (Fig. 1) . Structural Fig. 3 , ER(L543A/ L544A) and ER(M547A/L548A) generated normal amounts of complexes after ICI 164,384 treatment, which correlates with their strong transcriptional activation properties (see Fig.   2 ). The mutant ER(E546A) and ER(D542N/E546Q/D549N) behaved like ERwt (data not shown).
Since ICI 164,384 has been shown to decrease the cellular levels of ER (25, 26) , we determined the effect of the antiestrogens on the levels of mutant receptors by Western blotting to test if reduced binding activity is due to reduced receptor levels (Fig. 4A) Histochemical studies have shown that the ERwt protein is located predominantly in the nucleus in the absence or presence of hormone (27) . A similar study with transfected Cos-1 cells, which showed that, while 4-OHT had no effect on the nuclear localization of ERwt, ICI 164,384 resulted in a rapid loss of nuclear in favor of cytoplasmic localization of ERwt (Fig. 4B, Top) . In contrast, ER(L543A/L544A) and ER(M547A/L548A) were nuclear not only in the presence of 173-estradiol (Fig. 4B , Middle and Bottom Left) or 4-OHT (not shown) but also after ICI 164,384 treatment (Fig. 4B , Middle and Bottom Right).
Previous work had demonstrated that the agonist activity of tamoxifen is mediated by AF-1 (20) . Therefore, we tested the importance of this domain in the mutant receptors by analyzing the transcriptional activity of the same mutations as above but in MOR-(121-599), which lacks AF-1. The DNA-binding activity of these mutant receptors was similar to that of the mutated full-length receptors irrespective of the ligand bound (data not shown). However, mutations in the charged residues of the truncated receptor reduced the basal activity of the reporter gene compared to that obtained with the wild-type receptor but showed a similar 3-to 4-fold response to estradiol (Fig. 5) . Both antiestrogens abolished the estrogen-dependent E-546Q 
